8-K: Clover Health Sees 53% MA Growth, Targets 2026 Profit

Clover Health announced a 53% year-over-year increase in Medicare Advantage membership to 153,000, projecting its first full year GAAP Net Income profitability in 2026.

Summary

• Medicare Advantage (MA) membership grew 53% year-over-year, reaching approximately 153,000 members as of January 1, 2026.
• The company expects to achieve its first-ever full year GAAP Net Income profitability in 2026.
• Over 97% of the January 1, 2026 MA membership is in its flagship PPO plan, which is ranked #1 nationally on core HEDIS quality measures for the second consecutive year.
• Clover Health maintained stable plan benefits year-over-year, resulting in over 95% AEP member retention.
• The company's PPO MA plans received a 4.0 Stars rating for payment year 2026.
• Growth was concentrated in established core markets, supported by Clover Assistant (CA) coverage and a differentiated Home Care offering.

Sentiment

Score: 9

Explanation: The filing presents exceptionally strong operational results with market-leading membership growth and high retention, coupled with a clear path to first-ever GAAP Net Income profitability. The consistent high Star Ratings and HEDIS performance underscore robust clinical quality and a differentiated model. While standard forward-looking risks are noted, the overall tone and specific metrics are overwhelmingly positive, indicating significant progress and a strong financial trajectory.

Positives

• 53% year-over-year Medicare Advantage membership growth, reaching 153,000 members as of January 1, 2026.
• Expectation of achieving first-ever full year GAAP Net Income profitability in 2026.
• Over 95% AEP member retention, indicating strong member satisfaction and loyalty.
• Flagship PPO plan ranked #1 nationally on core HEDIS quality measures for the second year in a row, with ~97% of MA membership in this plan.
• PPO MA plans achieved a 4.0 Stars rating for payment year 2026, providing a revenue tailwind.
• Favorable 2026 CMS final rate update and increased Part D direct subsidy are anticipated to improve cohort economics.
• Continued operating leverage and SG&A efficiency improvements with scale.
• Expansion of Clover Assistant for external payors and providers under the "Counterpart Assistant" brand.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks and uncertainties.
• Risks related to expectations regarding results of operations, financial condition, and cash flows.
• Risks regarding the development and management of the business.
• Impact of current, pending, or future legislation, regulations, or policies, including those related to healthcare, Medicare, and medical loss ratios.
• Ability to successfully enter new service markets and manage operations.
• Anticipated trends and challenges in the business and operating markets.
• Ability to effectively manage beneficiary base and provider network.
• Ability to maintain and increase adoption and use of Clover Assistant, including its expansion as Counterpart Assistant.
• Anticipated benefits associated with Clover Assistant, including its ability to manage medical expenses.
• Ability to maintain or improve Star Ratings or otherwise improve financial performance.
• Ability to develop new features and functionality that meet market needs and achieve market acceptance.
• Ability to retain and hire necessary employees and staff operations appropriately.
• Timing and amount of certain investments in growth.
• Outcome of any known and unknown litigation and regulatory proceedings.
• Ability to maintain, protect, and enhance intellectual property.
• General economic conditions and uncertainty, persistent high inflation, and fluctuating interest rates.
• Geopolitical uncertainty and instability.

Future Outlook

Clover Health anticipates achieving its first-ever full year GAAP Net Income profitability in 2026, driven by strong cohort economics, efficiencies from SG&A leverage, and optimization. The company expects meaningful new member cohort improvement and continued strong returning cohort performance, supported by a 4.0 Stars rating for PPO plans in payment year 2026, favorable 2026 CMS rate updates, increased Part D direct subsidies, and increased Clover Assistant coverage and PCP adoption. They also plan to accelerate Clover Assistant adoption to more clinicians beyond core MA plan markets through Counterpart Health.

Management Comments

• "This year's AEP performance shows what happens when robust plan benefits, Clover Assistant-enabled clinical performance, and a deepening market presence in local communities come together." Jamie Reynoso, CEO of Medicare Advantage.
• "We have replicated our AEP growth playbook from last year, and are proud to have exceeded our expectations in delivering market-leading growth this enrollment period. This is a direct result of targeted, sustainable, and concentrated growth in our core markets where we continue to scale Clover Assistant and Home Care to meet members where they are." Jamie Reynoso, CEO of Medicare Advantage.
• "We are entering 2026 on a strong financial trajectory. We believe this year will demonstrate the full power of Clover's model: significant member growth and strong returning member retention, layered onto meaningfully improving cohort performance and the continued impact of Clover Assistant. Together, we believe these dynamics will create compounding earnings and margin expansion over time, which we expect to position Clover to deliver its first year of GAAP Net Income profitability in 2026." Andrew Toy, Chief Executive Officer.

Industry Context

Clover Health's reported 53% Medicare Advantage membership growth stands out amidst a broader industry retreat, indicating strong competitive positioning and effective strategy in core markets. The focus on AI-powered clinical quality through Clover Assistant and a differentiated Home Care offering aligns with broader healthcare trends emphasizing value-based care, preventative health, and technology-driven efficiency to manage medical costs and improve patient outcomes. The company's ability to achieve market-leading growth and high retention while maintaining stable benefits suggests a strong value proposition in a competitive Medicare Advantage landscape.

Comparison to Industry Standards

• Clover Health's 53% Medicare Advantage membership growth is described as "market-leading" and achieved "amidst a broader industry retreat," suggesting outperformance compared to competitors.
• The flagship PPO plan is ranked #1 nationally on core HEDIS quality measures for the second year in a row, indicating superior clinical quality performance compared to other PPO Medicare Advantage plans nationwide.
• The company's PPO MA plans achieved a 4.0 Star Rating for payment year 2026, which is a strong rating that positively impacts revenue, positioning it favorably against plans with lower ratings.
• The filing highlights that "competitors signaling 2026 pullback" in core markets like New Jersey, where Clover achieved the largest net growth in 2025 and holds the #3 total MA market share and #2 Individual Non-SNP market share, demonstrating strong competitive gains.

Stakeholder Impact

• Shareholders: Positive impact due to significant membership growth, anticipated first-ever GAAP Net Income profitability, strong member retention, and high Star Ratings, which suggest improved financial performance and potential for compounding earnings and margin expansion.
• Members: Benefit from stable plan benefits, high-quality care (evidenced by #1 HEDIS ranking and 4.0 Star rating), and the continued use of Clover Assistant for earlier diagnosis and better management of chronic diseases.
• Healthcare Providers: Increased adoption and coverage of Clover Assistant and Counterpart Assistant can empower physicians with technology to improve clinical decision-making and patient outcomes.
• Employees: Continued growth and profitability may lead to job stability and potential expansion opportunities.

Next Steps

• CEO Andrew Toy to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2026.
• Focus on accelerating Clover Assistant adoption to more clinicians beyond core MA plan markets through Counterpart Health.
• Continued efforts to maintain industry-leading clinical quality and outcomes, including Stars improvement and increased coverage of Clover Assistant-powered care.
• Leveraging 4 Stars rating, strong retention, stable benefits, and industry pullback for market-leading, self-funded growth.

Key Dates

Recommendation

The filing indicates a significant positive inflection point for Clover Health. The reported 53% year-over-year Medicare Advantage membership growth is exceptional, especially in an environment where competitors are reportedly pulling back. This growth, combined with over 95% member retention and a 4.0 Star rating for PPO plans, establishes a robust foundation. The most compelling aspect is the clear expectation of achieving the company's first-ever full year GAAP Net Income profitability in 2026, driven by improving cohort economics and operational efficiencies. The consistent #1 national ranking on HEDIS quality measures for its flagship PPO plan further validates its differentiated, AI-powered clinical model. These factors collectively point to strong operational execution, a compelling value proposition, and a positive financial trajectory, making it a 'strong buy' for investors seeking growth and a path to sustained profitability in the healthcare sector.

Keywords

Clover Health, CLOV, Medicare Advantage, MA, Annual Election Period, AEP, GAAP Net Income, Profitability, HEDIS, Star Ratings, Clover Assistant, Healthcare Technology, PPO Plans, Member Growth, Health Insurance, CMS, Counterpart Health